Finnadvance produces organs-on-chip for preclinical drug testing and personalised medicine. We de-risk drug development by providing relevant in vitro models through the use of our organ-on-chip technology, named AKITA.
Our AKITA organ-on-chip platform predicts tumor drug resistance and can model the recruitment of immune cells and inflammation toward multiple tissues (lung, blood-brain barrier, gut, skin …). We can ship microfluidic plates for cultivation of own cells, ready-assay kits, or provide CRO in vitro service and personalised diagnostic.
Our patented technology is used in >20 countries worldwide by big pharmas, CROs and academic laboratories. We are looking forward for the development of joint models and fruitful collaborations.
